Frameworks for Valuing ASX and RMD Shares

2 min read | October 17, 2024 12:57 AM EDT | By Team Kalkine Media

Google News:

Frameworks for Valuing ASX and RMD Shares — Image source: Shutterstock

Recent News

Why Did WSP Global (TSX:WSP) Gain on UK Execution Shift in TSX 60?

Why Did Aecon Group (TSX:ARE) Gain on Churchill MOU in TSX Index?

Why Did Endeavour Silver (TSX:EDR) Gain on Terronera Drill Results in...

Why Did Maple Leaf Foods (TSX:MFI) Stock Dip After TSX Index Restructu...

Make Kalkine Media
My Trusted Source

Highlights:

ASX Limited has experienced a 4.9% increase in share price since the beginning of 2024, reflecting positive market sentiment.

ResMed CDI is currently trading approximately 66.9% above its 52-week low, indicating a potential recovery in share value.

Valuation metrics for ASX and ResMed suggest contrasting trends, with ASX shares trading slightly above their historical average, while RMD shares are below theirs.

ASX Limited operates Australia’s primary national securities exchange, providing a wide range of services, including securities and derivatives exchange services, central counterparty clearing, and registry services. The company facilitates access to various financial products such as shares, futures, exchange-traded funds (ETFs), managed funds, and real estate investment trusts (REITs). By overseeing compliance for listed companies, ASX aims to uphold high standards of corporate governance and create a level playing field for retail investors, thus playing a crucial role in the Australian financial market.

ResMed (ASX:RMD) ,founded in 1989, is a global leader in medical equipment focused on sleep and respiratory care. Headquartered in San Diego, California, ResMed provides cloud-connectable continuous positive airway pressure (CPAP) machines for the treatment of obstructive sleep apnea (OSA). With over 10,000 employees and operations in more than 140 countries, the company consists of two main business units: Sleep and Respiratory Care and Software as a Service (SaaS). ResMed’s innovative technology integrates hardware with software to enhance patient outcomes and streamline healthcare costs.

In terms of share price valuation, ASX Ltd currently has a price-to-sales ratio of 8.17, slightly above its five-year average of 8.12. This indicates a potential rise in share price or a decline in sales. In contrast, ResMed's price-to-sales ratio stands at 4.98, significantly lower than its long-term average of 8.70, suggesting that RMD shares are undervalued compared to historical performance.

Utilizing valuation metrics such as these can provide insights into market positioning, but it is essential to employ various methods for a comprehensive assessment. Resources are available through online platforms that offer courses on financial valuation techniques, including Discounted Cash Flow (DCF) and Dividend Discount Models (DDM).

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.